Показано 0 из 0
Дата |
---|
06.05.2024 |
03.05.2024 |
02.05.2024 |
01.05.2024 |
30.04.2024 |
29.04.2024 |
26.04.2024 |
25.04.2024 |
24.04.2024 |
23.04.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
8.25
|
8.95
|
8.60
|
8.42
|
8.91
|
8.81
|
|
|
848 246.83
|
1 680.00
|
8.25
|
9.00
|
8.79
|
8.55
|
9.09
|
8.56
|
|
|
780 717.73
|
1 288.00
|
8.28
|
8.81
|
8.76
|
8.55
|
8.8102
|
8.65
|
|
|
1 990 029.42
|
2 742.00
|
8.20
|
9.68
|
7.75
|
7.75
|
8.70
|
8.62
|
|
|
2 186 488.97
|
2 490.00
|
7.15
|
7.98
|
7.56
|
7.38
|
7.90
|
7.72
|
|
|
2 224 531.48
|
2 491.00
|
7.22
|
7.92
|
7.41
|
7.41
|
7.815
|
7.68
|
|
|
1 578 400.99
|
2 821.00
|
7.15
|
8.12
|
7.34
|
7.116
|
7.46
|
7.32
|
|
|
670 978.83
|
2 258.00
|
7.32
|
8.12
|
7.26
|
7.035
|
7.4574
|
7.29
|
|
|
776 669.96
|
1 855.00
|
7.00
|
8.12
|
7.28
|
7.11
|
7.51
|
7.38
|
|
|
666 059.24
|
1 897.00
|
6.18
|
7.44
|
7.22
|
7.02
|
7.55
|
7.26
|
|
|
1 514 090.21
|
4 235.00
|
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.